LINZESS

This brand name is authorized in Hong Kong, Japan, United States

Active ingredients

The drug LINZESS contains one active pharmaceutical ingredient (API):

1 Linaclotide
UNII N0TXR0XR5X - LINACLOTIDE

Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans.

Read about Linaclotide

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
LINZESS Capsule, gelatin coated FDA, National Drug Code (US) MPI, US: SPL/PLR

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: HK Department of Health Drug Office Identifier(s): 64139
Country: JP 医薬品医療機器総合機構 Identifier(s): 2399017F1020
Country: US FDA, National Drug Code Identifier(s): 0456-1201, 0456-1202, 0456-1203

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.